Dr. Kahl on Findings From the L-MIND Study With Tafasitamab in DLBCL

Brad S. Kahl, MD, a medical oncologist at Siteman Cancer Center and a professor of medicine in the Division of Oncology at Washington University School of Medicine in St. Louis, discusses findings from the phase 2 L-MIND study in diffuse large B-cell lymphoma (DLBCL).

The monoclonal antibody tafasitamab (MOR208), which targets CD19, and lenalidomide (Revlimid) is a promising treatment option for patients with relapsed/refractory DLBCL, says Kahl. In the L-MIND study, lenalidomide was given for a year and tafasitamab was given weekly for the first 3 months and then every other week, indefinitely.

Overall, it appears to be a well-tolerated regimen with a high response rate of 60% and a complete response rate of 42%. The most impressive result was the durability of those responses, says Kahl.The majority of patients were still in remission at 18 months.

As such, if a patient is being treated with palliative intent and is no longer considered for curative intention therapies, such as autologous stem cell transplant or CAR T-cell therapy, the tafasitamab regimen is a fantastic option for those patients, concludes Kahl.